ICA Group Wealth Management LLC Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ICA Group Wealth Management LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 82.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51 shares of the biopharmaceutical company’s stock after selling 244 shares during the quarter. ICA Group Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $54,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sachetta LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. West Paces Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on REGN shares. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Truist Financial restated a “buy” rating and issued a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 2nd. TD Cowen upped their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Barclays upped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1,109.70.

Regeneron Pharmaceuticals Stock Down 1.0 %

NASDAQ:REGN opened at $1,153.35 on Monday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock’s fifty day moving average is $1,124.22 and its two-hundred day moving average is $1,026.46. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The stock has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.07, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same period in the prior year, the firm earned $8.79 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the sale, the executive vice president now owns 37,937 shares in the company, valued at $41,311,496.15. The disclosure for this sale can be found here. Insiders have sold 10,026 shares of company stock worth $11,498,705 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.